يعرض 821 - 840 نتائج من 1,182 نتيجة بحث عن '(( significant decrease decrease ) OR ( significantly small decrease ))~', وقت الاستعلام: 0.40s تنقيح النتائج
  1. 821

    Supplementary file 1_Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells.jpeg حسب Donatella Treppiedi (10146335)

    منشور في 2025
    "…Moreover, SRPIN340 significantly decreased both transcript (-56.3 (38.6)%, p<0.01 vs control cells) and protein levels (-33.5 (3.4)%, p<0.05 vs control cells) of the pro-survival VEGF164a isoform. …"
  2. 822

    Image 1_Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells.jpg حسب Donatella Treppiedi (10146335)

    منشور في 2025
    "…Moreover, SRPIN340 significantly decreased both transcript (-56.3 (38.6)%, p<0.01 vs control cells) and protein levels (-33.5 (3.4)%, p<0.05 vs control cells) of the pro-survival VEGF164a isoform. …"
  3. 823

    Speech sound difficulties, language and reading (Walquist-Sørli et al., 2025) حسب Line Walquist-Sørli (20285493)

    منشور في 2025
    "…However, a precision-effect test and the precision-effect estimate with standard errors analysis suggested a potential decrease in effect size due to publication bias from small sample sizes in primary studies.…"
  4. 824

    Table 1_Evaluation of environmental risk factors associated with survival of generic E. coli in organic integrated crop-livestock systems in California and Minnesota.docx حسب Annette Kenney (14843218)

    منشور في 2024
    "…Concentrations (Most Probable Number/100 g) of gEc in grazed soil returned to levels comparable to non-grazed or fallow treatments within 87–147 days post-graze (DPG) in both years, with a significant decrease predicted after 32 DPG. Interestingly, non-O157 STEC was detected in soil even after concentrations of gEc declined 115–147 DPG.…"
  5. 825

    Analyses of directed phase lag index (dPLI [44]) for excitatory/inhibitory (E/I) ratios with respect to pyramidal (Pyr) and parvalbumin (PV) populations (<i>A</i>) and Pyr and soma... حسب Nobuhiko Wagatsuma (494052)

    منشور في 2025
    "…Values of dPLI from PV to Pyr and from SOM to Pyr populations for each trial are shown by small black and gray circles, respectively. <b><i>A.…"
  6. 826

    Included studies basic characteristics. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  7. 827

    Forest plot for FVC. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  8. 828

    All data extracted. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  9. 829

    Forest plot for TNF- حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  10. 830

    <b>Exploring left lateral decubitus position, and its influence on infant mortality in pregnant women in their third trimester, brought to the emergency through the GVK Ambulance S... حسب Laggy George (19873020)

    منشور في 2024
    "…</p><p dir="ltr">Conclusion:</p><p dir="ltr">Transporting mothers in a Left Lateral Decubitus position may significantly decrease the odds of Infant mortality by 62%; after adjusting for antenatal care visits. …"
  11. 831

    Comparison of the trend of people’s perceptions and the climatic trends (social data: Quantitative data: Household survey (n = 660); qualitative data: Focus group discussions (n =... حسب Parbati Phuyal (8687400)

    منشور في 2025
    "…Brackets indicate only a small trend (climate = one or a few significant indices, temporal shift = no significant trend). …"
  12. 832

    Bias risk assessment of included studies. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  13. 833

    Forest plot for hs-CRP. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  14. 834

    Forest plot for IL-6. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  15. 835

    The incidence rate of adverse reactions. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  16. 836

    The PRISMA study flowchart. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  17. 837

    Forest plot for FEV1/FVC. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  18. 838

    Forest plot for clinical efficacy. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  19. 839

    Forest plot for FEV1. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"
  20. 840

    The excluded and included studies were listed. حسب Xuqin Du (8803772)

    منشور في 2025
    "…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"